{"id":15764,"date":"2025-10-17T22:18:30","date_gmt":"2025-10-17T15:18:30","guid":{"rendered":"https:\/\/nhathuocngocanh.com\/bp\/?p=15764"},"modified":"2025-10-17T22:18:30","modified_gmt":"2025-10-17T15:18:30","slug":"galantamine-oral-solution","status":"publish","type":"post","link":"https:\/\/nhathuocngocanh.com\/bp\/galantamine-oral-solution\/","title":{"rendered":"Galantamine Oral Solution"},"content":{"rendered":"

BP 2025 (Ph. Eur. 11.6 update)<\/p>\n

Action and use<\/strong><\/p>\n

Cholinesterase inhibitor; treatment of Alzheimer\u2019s disease.<\/p>\n

DEFINITION<\/h2>\n
Galantamine Oral Solution is a solution containing Galantamine Hydrobromide in a suitable aqueous vehicle.<\/p>\n
The oral solution complies with the requirements stated under Oral Liquids and with the following requirements.<\/p>\n
Content of galantamine, C_{17<\/sub>H_{21<\/sub>NO_{3<\/sub><\/strong><\/p>\n}}}
95.0 to 105.0% of the stated amount.<\/p>\n
IDENTIFICATION<\/h2>\n
A. Carry out the method for thin-layer chromatography, Appendix III A, using the following solutions.
\n(1) To a volume of the oral solution containing the equivalent of 2 mg of galantamine, add 10 mL of acetonitrile, centrifuge and use the supernatant liquid.
\n(2) 0.026% w\/v of galantamine hydrobromide BPCRS in acetonitrile.<\/p>\n
CHROMATOGRAPHIC CONDITIONS<\/h3>\n
(a) Use as the coating silica gel (Merck silica gel 60 plates are suitable).
\n(b) Use the mobile phase as described below.
\n(c) Apply 10 \u03bcL of each solution.
\n(d) Develop the plate to 8 cm.
\n(e) After removal of the plate, dry in air and spray with potassium iodobismuthate solution, then immediately with hydrogen peroxide solution (3 per cent). Examine the plate in white light.<\/p>\n
MOBILE PHASE<\/h3>\n
1 volume of glacial acetic acid, 4 volumes of butan-1-ol and 5 volumes of water.<\/p>\n
CONFIRMATION<\/h3>\n
The principal spot in the chromatogram obtained with solution (1) is similar in position, colour and size to that in the chromatogram obtained with solution (2).
\nB. In the Assay, the retention time of the principal peak in the chromatogram obtained with solution (1) is similar to that of the peak in the chromatogram obtained with solution (2).<\/p>\n
TESTS<\/h2>\n
Acidity<\/strong><\/p>\n
pH, 4.0 to 6.0, Appendix V L.<\/p>\n
Related substances<\/strong><\/p>\n
Carry out the method for liquid chromatography, Appendix III D, using the following solutions in methanol (50%).<\/p>\n
(1) Dilute a volume of the oral solution containing the equivalent of 0.1 g of galantamine to 100 mL.
\n(2) Dilute 1 volume of solution (1) to 200 volumes.
\n(3) 0.05% w\/v of galantamine natural for system suitability EPCRS.
\n(4) 0.05% w\/v of galantamine synthetic for system suitability EPCRS.
\n(5) 0.1% w\/v of galantamine hydrobromide impurity standard BPCRS.
\n(6) Dilute 1 volume of solution (2) to 5 volumes.<\/p>\n
CHROMATOGRAPHIC CONDITIONS<\/h3>\n
(a) Use a stainless steel column (10 cm \u00d7 4.6 mm) packed with end-capped octadecylsilyl amorphous organosilica
\npolymer for chromatography (3.5 \u03bcm) (Waters XTerra MS C18 is suitable).
\n(b) Use gradient elution and the mobile phase described below.
\n(c) Use a flow rate of 1.5 mL per minute.
\n(d) Use a column temperature of 55\u00b0.
\n(e) Use a detection wavelength of 230 nm.
\n(f) Inject 20 \u03bcL of each solution.<\/p>\n
MOBILE PHASE<\/h3>\n
Mobile phase A<\/em> 5 volumes of methanol and 95 volumes of a solution containing 0.079% w\/v of disodium hydrogen orthophosphate dihydrate and 0.246% w\/v of sodium dihydrogen orthophosphate.<\/p>\n
Mobile phase B<\/em> acetonitrile.<\/p>\n\n\n\n\n\n\n\n\n\n
Time (Minutes)<\/td>\n Mobile phase A (% v\/v)<\/td>\n Mobile phase B (% v\/v)<\/td>\n Comment<\/td>\n<\/tr>\n
0-6<\/td>\n 100<\/td>\n 0<\/td>\n isocratic<\/td>\n<\/tr>\n
6-20<\/td>\n 100\u219295<\/td>\n 0\u21925<\/td>\n linear gradient<\/td>\n<\/tr>\n
20-35<\/td>\n 95\u219285<\/td>\n 5\u219215<\/td>\n linear gradient<\/td>\n<\/tr>\n
35-50<\/td>\n 85\u219280<\/td>\n 15\u219220<\/td>\n linear gradient<\/td>\n<\/tr>\n
50-51<\/td>\n 80\u2192100<\/td>\n 20\u21920<\/td>\n linear gradient<\/td>\n<\/tr>\n
51-60<\/td>\n 100<\/td>\n 0<\/td>\n re-equilibration<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
When the chromatograms are recorded under the prescribed conditions, the relative retentions with reference to galantamine (retention time about 18 minutes) are: impurity E, about 0.3; impurity 2, about 0.4; impurity 1, about 0.6; impurity C, about 0.8; impurity B, about 1.1; impurity A, about 1.5 and impurity D, about 1.9.<\/p>\n
SYSTEM SUITABILITY<\/h3>\n
The test is not valid unless, in the chromatogram obtained with solution (4), the resolution between the peaks due to impurity C and galantamine is at least 4.5.<\/p>\n
LIMITS<\/h3>\n
Identify any peaks in the chromatogram obtained with solution (1) corresponding to:<\/p>\n
impurities A and E using the chromatogram obtained with solution (3) and the chromatogram supplied with galantamine natural for system suitability EPCRS;<\/p>\n
impurities C and D using the chromatogram obtained with solution (4) and the chromatogram supplied with galantamine synthetic for system suitability EPCRS;<\/p>\n
impurities B, 1, and 2 using the chromatogram obtained with solution (5) and the chromatogram supplied with galantamine hydrobromide impurity standard BPCRS.<\/p>\n
Multiply the area of any peak corresponding to impurity A by a correction factor of 0.5.<\/p>\n
In the chromatogram obtained with solution (1):<\/p>\n
the area of any peak corresponding to impurity E is not greater than 1.2 times the area of the principal peak in the chromatogram obtained with solution (2) (0.6%);<\/p>\n
the area of any peak corresponding to impurity B, C, D, 1, or 2 is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (0.5% of each);<\/p>\n
the area of any other secondary peak is not greater than 0.4 times the area of the principal peak in the chromatogram obtained with solution (2) (0.2%);<\/p>\n
the sum of the areas of all secondary peaks is not greater than 3 times the area of the principal peak in the chromatogram obtained with solution (2) (1.5%).<\/p>\n
Disregard any peak with an area less than the area of the principal peak in the chromatogram obtained with solution (6) (0.1%).<\/p>\n
ASSAY<\/h2>\n
Carry out the method for liquid chromatography, Appendix III D, using the following solutions.<\/p>\n
Solution A 0.4% w\/v potassium dihydrogen orthophosphate, adjusted to pH 6.5 with 5M sodium hydroxide.
\n(1) To a weighed quantity of the oral solution containing the equivalent of 25 mg of galantamine add 10 mL of methanol,
\nand add sufficient of solution A to produce 50 mL. Dilute 1 volume of this solution to 10 volumes with solution A.
\n(2) Dissolve 16 mg of galantamine hydrobromide BPCRS in 5 mL of methanol, and dilute to 25 mL with solution A. Dilute
\n1 mL of the resulting solution to 10 volumes with solution A.
\n(3) 0.05% w\/v of galantamine synthetic for system suitability EPCRS in methanol (50%).<\/p>\n
CHROMATOGRAPHIC CONDITIONS<\/h3>\n
(a) Use a stainless steel column (10 cm \u00d7 4.6 mm) packed with end-capped octadecylsilyl amorphous organosilica
\npolymer for chromatography (3.5 \u03bcm) (Waters XTerra MS C18 is suitable).
\n(b) Use isocratic elution and the mobile phase described below.
\n(c) Use a flow rate of 1.5 mL per minute.
\n(d) Use a column temperature of 55\u00b0.
\n(e) Use a detection wavelength of 230 nm.
\n(f) Inject 20 \u03bcL of each solution.<\/p>\n
MOBILE PHASE<\/h3>\n
5 volumes of methanol and 95 volumes of a solution containing 0.079% w\/v of disodium hydrogen orthophosphate dihydrate and 0.246% w\/v of sodium dihydrogen orthophosphate.<\/p>\n
SYSTEM SUITABILITY<\/h3>\n
The test is not valid unless, in the chromatogram obtained with solution (3), the resolution between the peaks due to impurity C and galantamine is at least 4.5.<\/p>\n
DETERMINATION OF CONTENT<\/h3>\n
Determine the weight per mL of the oral solution, Appendix V G, and calculate the content of C_{17<\/sub>H_{21<\/sub>NO_{3<\/sub>, in the oral solution using the declared content of C_{17<\/sub>H_{21<\/sub>NO_{3<\/sub> in galantamine hydrobromide BPCRS.<\/p>\n}}}}}}
LABELLING<\/p>\n
The quantity of active ingredient is stated in terms of the equivalent amount of galantamine.<\/p>\n
IMPURITIES<\/p>\n
The impurities limited by the requirements of this monograph include impurities A to E listed under Galantamine Hydrobromide and:<\/p>\n
$\"galantamine-N-oxide\"$
\n1. galantamine-N-oxide<\/p>\n
$\"O-demethylgalantamine\"$
\n2. O-demethylgalantamine<\/p>\n","protected":false},"excerpt":{"rendered":"
BP 2025 (Ph. Eur. 11.6 update) Action and use Cholinesterase inhibitor; treatment of Alzheimer\u2019s disease. DEFINITION Galantamine Oral Solution is a solution containing Galantamine Hydrobromide in a suitable aqueous vehicle. The oral solution complies with the requirements stated under Oral Liquids and with the following requirements. Content of galantamine, C17H21NO3 95.0 to 105.0% of the…<\/p>\n","protected":false},"author":5,"featured_media":15765,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[175],"tags":[],"class_list":["post-15764","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-formulated-preparations-specific-monographs"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/15764","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=15764"}],"version-history":[{"count":2,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/15764\/revisions"}],"predecessor-version":[{"id":15771,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/15764\/revisions\/15771"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/15765"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=15764"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=15764"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=15764"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

Time (Minutes)<\/td>\n	Mobile phase A (% v\/v)<\/td>\n	Mobile phase B (% v\/v)<\/td>\n	Comment<\/td>\n<\/tr>\n
0-6<\/td>\n	100<\/td>\n	0<\/td>\n	isocratic<\/td>\n<\/tr>\n
6-20<\/td>\n	100\u219295<\/td>\n	0\u21925<\/td>\n	linear gradient<\/td>\n<\/tr>\n
20-35<\/td>\n	95\u219285<\/td>\n	5\u219215<\/td>\n	linear gradient<\/td>\n<\/tr>\n
35-50<\/td>\n	85\u219280<\/td>\n	15\u219220<\/td>\n	linear gradient<\/td>\n<\/tr>\n
50-51<\/td>\n	80\u2192100<\/td>\n	20\u21920<\/td>\n	linear gradient<\/td>\n<\/tr>\n
51-60<\/td>\n	100<\/td>\n	0<\/td>\n	re-equilibration<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n When the chromatograms are recorded under the prescribed conditions, the relative retentions with reference to galantamine (retention time about 18 minutes) are: impurity E, about 0.3; impurity 2, about 0.4; impurity 1, about 0.6; impurity C, about 0.8; impurity B, about 1.1; impurity A, about 1.5 and impurity D, about 1.9.<\/p>\n SYSTEM SUITABILITY<\/h3>\n The test is not valid unless, in the chromatogram obtained with solution (4), the resolution between the peaks due to impurity C and galantamine is at least 4.5.<\/p>\n LIMITS<\/h3>\n Identify any peaks in the chromatogram obtained with solution (1) corresponding to:<\/p>\n impurities A and E using the chromatogram obtained with solution (3) and the chromatogram supplied with galantamine natural for system suitability EPCRS;<\/p>\n impurities C and D using the chromatogram obtained with solution (4) and the chromatogram supplied with galantamine synthetic for system suitability EPCRS;<\/p>\n impurities B, 1, and 2 using the chromatogram obtained with solution (5) and the chromatogram supplied with galantamine hydrobromide impurity standard BPCRS.<\/p>\n Multiply the area of any peak corresponding to impurity A by a correction factor of 0.5.<\/p>\n In the chromatogram obtained with solution (1):<\/p>\n the area of any peak corresponding to impurity E is not greater than 1.2 times the area of the principal peak in the chromatogram obtained with solution (2) (0.6%);<\/p>\n the area of any peak corresponding to impurity B, C, D, 1, or 2 is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (0.5% of each);<\/p>\n the area of any other secondary peak is not greater than 0.4 times the area of the principal peak in the chromatogram obtained with solution (2) (0.2%);<\/p>\n the sum of the areas of all secondary peaks is not greater than 3 times the area of the principal peak in the chromatogram obtained with solution (2) (1.5%).<\/p>\n Disregard any peak with an area less than the area of the principal peak in the chromatogram obtained with solution (6) (0.1%).<\/p>\n ASSAY<\/h2>\n Carry out the method for liquid chromatography, Appendix III D, using the following solutions.<\/p>\n Solution A 0.4% w\/v potassium dihydrogen orthophosphate, adjusted to pH 6.5 with 5M sodium hydroxide. \n(1) To a weighed quantity of the oral solution containing the equivalent of 25 mg of galantamine add 10 mL of methanol, \nand add sufficient of solution A to produce 50 mL. Dilute 1 volume of this solution to 10 volumes with solution A. \n(2) Dissolve 16 mg of galantamine hydrobromide BPCRS in 5 mL of methanol, and dilute to 25 mL with solution A. Dilute \n1 mL of the resulting solution to 10 volumes with solution A. \n(3) 0.05% w\/v of galantamine synthetic for system suitability EPCRS in methanol (50%).<\/p>\n CHROMATOGRAPHIC CONDITIONS<\/h3>\n (a) Use a stainless steel column (10 cm \u00d7 4.6 mm) packed with end-capped octadecylsilyl amorphous organosilica \npolymer for chromatography (3.5 \u03bcm) (Waters XTerra MS C18 is suitable). \n(b) Use isocratic elution and the mobile phase described below. \n(c) Use a flow rate of 1.5 mL per minute. \n(d) Use a column temperature of 55\u00b0. \n(e) Use a detection wavelength of 230 nm. \n(f) Inject 20 \u03bcL of each solution.<\/p>\n MOBILE PHASE<\/h3>\n 5 volumes of methanol and 95 volumes of a solution containing 0.079% w\/v of disodium hydrogen orthophosphate dihydrate and 0.246% w\/v of sodium dihydrogen orthophosphate.<\/p>\n SYSTEM SUITABILITY<\/h3>\n The test is not valid unless, in the chromatogram obtained with solution (3), the resolution between the peaks due to impurity C and galantamine is at least 4.5.<\/p>\n DETERMINATION OF CONTENT<\/h3>\n Determine the weight per mL of the oral solution, Appendix V G, and calculate the content of C_{17<\/sub>H_{21<\/sub>NO_{3<\/sub>, in the oral solution using the declared content of C_{17<\/sub>H_{21<\/sub>NO_{3<\/sub> in galantamine hydrobromide BPCRS.<\/p>\n}}}}}} LABELLING<\/p>\n The quantity of active ingredient is stated in terms of the equivalent amount of galantamine.<\/p>\n IMPURITIES<\/p>\n The impurities limited by the requirements of this monograph include impurities A to E listed under Galantamine Hydrobromide and:<\/p>\n $\"galantamine-N-oxide\"$ \n1. galantamine-N-oxide<\/p>\n $\"O-demethylgalantamine\"$ \n2. O-demethylgalantamine<\/p>\n","protected":false},"excerpt":{"rendered":" BP 2025 (Ph. Eur. 11.6 update) Action and use Cholinesterase inhibitor; treatment of Alzheimer\u2019s disease. DEFINITION Galantamine Oral Solution is a solution containing Galantamine Hydrobromide in a suitable aqueous vehicle. The oral solution complies with the requirements stated under Oral Liquids and with the following requirements. Content of galantamine, C17H21NO3 95.0 to 105.0% of the…<\/p>\n","protected":false},"author":5,"featured_media":15765,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[175],"tags":[],"class_list":["post-15764","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-formulated-preparations-specific-monographs"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/15764","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=15764"}],"version-history":[{"count":2,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/15764\/revisions"}],"predecessor-version":[{"id":15771,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/15764\/revisions\/15771"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/15765"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=15764"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=15764"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=15764"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

MOBILE PHASE<\/h3>\n1 volume of glacial acetic acid, 4 volumes of butan-1-ol and 5 volumes of water.<\/p>\n

SYSTEM SUITABILITY<\/h3>\nThe test is not valid unless, in the chromatogram obtained with solution (4), the resolution between the peaks due to impurity C and galantamine is at least 4.5.<\/p>\n

MOBILE PHASE<\/h3>\n5 volumes of methanol and 95 volumes of a solution containing 0.079% w\/v of disodium hydrogen orthophosphate dihydrate and 0.246% w\/v of sodium dihydrogen orthophosphate.<\/p>\n

SYSTEM SUITABILITY<\/h3>\nThe test is not valid unless, in the chromatogram obtained with solution (3), the resolution between the peaks due to impurity C and galantamine is at least 4.5.<\/p>\n

MOBILE PHASE<\/h3>\n
1 volume of glacial acetic acid, 4 volumes of butan-1-ol and 5 volumes of water.<\/p>\n

SYSTEM SUITABILITY<\/h3>\n
The test is not valid unless, in the chromatogram obtained with solution (4), the resolution between the peaks due to impurity C and galantamine is at least 4.5.<\/p>\n

MOBILE PHASE<\/h3>\n
5 volumes of methanol and 95 volumes of a solution containing 0.079% w\/v of disodium hydrogen orthophosphate dihydrate and 0.246% w\/v of sodium dihydrogen orthophosphate.<\/p>\n

SYSTEM SUITABILITY<\/h3>\n
The test is not valid unless, in the chromatogram obtained with solution (3), the resolution between the peaks due to impurity C and galantamine is at least 4.5.<\/p>\n